INVESTOR RELATIONS

Omega Pharma Full IFRS Annual Report 2014

Read the full IFRS Annual Report 2014

Convocation and agenda for the Annual Shareholders Meeting and Extraordinary Shareholders Meeting of 28 April 2015 - Click here.


 

Omega Pharma Full IFRS Annual Report 2013

Read the full IFRS Annual Report 2013

Convocation and agenda for the Annual Shareholders Meeting of 22 April 2014 - Click here


 

Omega Pharma Interim Financial Report 2013

Read the Omega Pharma Interim Financial Report 2013

Convocation and agenda for the Annual Shareholders Meeting of 23 April 2013 - Click here


 

In April-May 2012, Omega Pharma raised the maximum expected amount of 300 million euros after the first subscription day for two Retail Bonds

Both bonds are listed on the Luxemburg Stock Exchange

Omega Pharma NV has chosen Luxembourg as its "Home Member State" pursuant to the Luxembourg Transparency Law of 11 January 2008. Article 22 of this Law specifies that the Luxembourg Commission de Surveillance de Secteur Financier (CSSF) is the competent authority for ensuring that the provisions of the Transparency Law are applied.
 
 

Note: investor information on Omega Pharma Invest (the holding company above Omega Pharma) can be found on a separate website


 

Omega Pharma is a private company since its delisting from NYSE Euronext Brussels on February 3, 2012.

The shareholding structure is as follows: Omega Pharma Invest NV owns 87.74 per cent of the shares and the company holds 12.26 per cent treasury shares. In turn, Omega Pharma Invest NV is controlled and fully owned by: Alychlo NV (49.56 per cent), Holdco I BE NV (49.57 per cent) and certain members of the management (0.86 per cent). Marc Coucke is principal shareholder of Alychlo NV. Holdco I BE BV (a private company uner Dutch law) holds 61.6 per cent of Holdco I BE NV. Waterland Private Equity Fund V CV holds all shares of Holdco I BE BV. Hao Investments holds 38.4 per cent of the shares of Holdco I BE NV.


 

Information on the succesfully completed voluntary public takeover bid by Couckinvest (September 2011 - February 2012)

After the squeeze-out procedure (that ran until 3 February 2012), Couckinvest holds/controls 99.26% of all shares outstanding. Payment of the shares tendered during the squeeze-out procedure is scheduled for 17 February 2012.The remaining non-tendered shares are deemed transferred to Couckinvest NV by operation of law. These shareholders remain entitled to receive EUR 36 per share and should contact to that end the Belgian Deposit and Consignation Office where the corresponding funds will remain available for a period of thirty years. More information can be found in the corresponding prospectus and under the section "Press Releases" (2011-2012).